Corrigendum to 'Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828]

Pasi A Jänne¹, Yasushi Goto², Toshio Kubo³, Kiichiro Ninomiya⁴, Sang-We Kim⁵, David Planchard⁶, Myung-Ju Ahn⁷, Egbert Smit⁸, Adrianus Johannes de Langen⁹, Maurice Pérol¹⁰, Elvire Pons-Tostivint¹¹, Silvia Novello¹², Hidetoshi Hayashi¹³, Junichi Shimizu¹⁴, Dong-Wan Kim¹⁵, Kaline Pereira¹⁶, Fu-Chih Cheng¹⁶, Ayumi Taguchi¹⁷, Yingkai Cheng¹⁶, Kyle Dunton¹⁸, Ahmed Ali¹⁹, Koichi Goto²⁰

Affiliations

¹ Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: pasi_janne@dfci.harvard.edu.
² Department of Thoracic Oncology, National Cancer Central Hospital, Tokyo, Japan.
³ Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan.
⁴ Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
⁵ Oncology Department, Asan Medical Center, Seoul, and University of Ulsan College of Medicine, Ulsan, Republic of Korea.
⁶ Department of Medical Oncology, Thoracic Cancer Group, Gustave Roussy, and Faculty of Medicine, Paris-Saclay University, Paris, France.
⁷ Department of Hematology and Oncology, Samsung Medical Center Sungkyunkwan, and University School of Medicine, Seoul, Republic of Korea.
⁸ Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, The Netherlands.
⁹ Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
¹⁰ Department of Medical Oncology, Léon Berard Centre, Lyon, France.
¹¹ Centre Hospitalier Universitaire Nantes, Nantes University, Nantes, Cedex, France.
¹² Department of Oncology, University of Turin, Turin, and Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, Italy.
¹³ Department of Medical Oncology, Kindai University Hospital, Osaka, Japan.
¹⁴ Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya City, Japan.
¹⁵ Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea.
¹⁶ Daiichi Sankyo, Basking Ridge, New Jersey.
¹⁷ Daiichi Sankyo, Tokyo, Japan.
¹⁸ Daiichi Sankyo UK, Uxbridge, United Kingdom.
¹⁹ Daiichi Sankyo Europe GmbH, Munich, Germany.
²⁰ Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.

PMID: 41729148
DOI: 10.1016/j.jtho.2026.103557

Free article

Published Erratum

Corrigendum to 'Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828]

Pasi A Jänne et al. J Thorac Oncol. 2026.

Free article

. 2026 Feb 23:103557.

doi: 10.1016/j.jtho.2026.103557. Online ahead of print.

Authors

Affiliations

¹ Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: pasi_janne@dfci.harvard.edu.
² Department of Thoracic Oncology, National Cancer Central Hospital, Tokyo, Japan.
³ Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan.
⁴ Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
⁵ Oncology Department, Asan Medical Center, Seoul, and University of Ulsan College of Medicine, Ulsan, Republic of Korea.
⁶ Department of Medical Oncology, Thoracic Cancer Group, Gustave Roussy, and Faculty of Medicine, Paris-Saclay University, Paris, France.
⁷ Department of Hematology and Oncology, Samsung Medical Center Sungkyunkwan, and University School of Medicine, Seoul, Republic of Korea.
⁸ Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, The Netherlands.
⁹ Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
¹⁰ Department of Medical Oncology, Léon Berard Centre, Lyon, France.
¹¹ Centre Hospitalier Universitaire Nantes, Nantes University, Nantes, Cedex, France.
¹² Department of Oncology, University of Turin, Turin, and Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano, Italy.
¹³ Department of Medical Oncology, Kindai University Hospital, Osaka, Japan.
¹⁴ Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya City, Japan.
¹⁵ Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea.
¹⁶ Daiichi Sankyo, Basking Ridge, New Jersey.
¹⁷ Daiichi Sankyo, Tokyo, Japan.
¹⁸ Daiichi Sankyo UK, Uxbridge, United Kingdom.
¹⁹ Daiichi Sankyo Europe GmbH, Munich, Germany.
²⁰ Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.

PMID: 41729148
DOI: 10.1016/j.jtho.2026.103557

No abstract available

PubMed Disclaimer

Erratum for

Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC.
Jänne PA, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, Ahn MJ, Smit E, Johannes de Langen A, Pérol M, Pons-Tostivint E, Novello S, Hayashi H, Shimizu J, Kim DW, Pereira K, Cheng FC, Taguchi A, Cheng Y, Dunton K, Ali A, Goto K. Jänne PA, et al. J Thorac Oncol. 2025 Dec;20(12):1814-1828. doi: 10.1016/j.jtho.2025.07.129. Epub 2025 Jul 30. J Thorac Oncol. 2025. PMID: 40749900 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Corrigendum to 'Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828]

Affiliations

Corrigendum to 'Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828]

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous